资讯
6 小时
MyChesCo on MSNKite to Buy Interius BioTherapeutics for $350 Million, Advancing In Vivo CAR T Strategy
Kite, a Gilead company (Nasdaq: GILD), has agreed to acquire Interius BioTherapeutics for $350 million in cash, a move aimed at bringing in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果